

NOVEL EMERGING SUBSTANCES



Axis Forensic Toxicology leads the industry in designer drug testing

AXIS' NOVEL EMERGING SUBSTANCES PANEL GIVES VISIBILITY TO THE PRESENCE OF THESE COMPOUNDS IN YOUR AREA

Why a Novel Emerging Substances Panel?

- Novel substances can disappear as quickly as they appear, placing challenges on laboratories to develop detection methods quickly.
- These compounds are frequently found mixed with other, routinely identified compounds such as fentanyl or methamphetamine.
- In the current focus on public health, many jurisdictions want to be sure they are identifying the full scope of impactful compounds.
- There is insufficient data to determine the impact of a given concentration.
- This panel is designed to be focused on detection and rapidly updated.
- Results are reported qualitatively from our high-resolution screening method using a second aliquot of the specimen.

Current Analytes

7-Hydroxymitragynine	BTMPS
Alpha-PHP	Dex/Levo Medetomidine
Alpha-PHPP (PV8)	Diphenidine
Alpha-PiHP	MDPHP
Alpha-PiHPP (Iso-PV8)	Mitragynine Pseudoindoxyl
Alpha-PipHP	Phenibut
AP-237	Tianeptine
AP-238	

Screening for novel emerging compounds is now included with Analyte Assurance™, a feature of Axis' Comprehensive Panels.

SMR372 V10.0 Effective Date 04/20/2026